TREATMENT OF CUTANEOUS LEISHMANIASIS

被引：72

作者：

KOFF, AB ^{[1
]}

ROSEN, T ^{[1
]}

机构：

[1] BAYLOR COLL MED, DEPT DERMATOL, HOUSTON, TX 77030 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 1994年 / 31卷 / 05期

关键词：

D O I：

10.1016/S0190-9622(94)70229-2

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

The World Health Organization estimates that approximately 400,000 new cases of leishmaniasis occur worldwide each year. Cutaneous leishmaniasis is being encountered more frequently in the United States because of increasing travel and immigration from endemic areas. The indications for treatment and recommended treatment regimens reported in the infectious disease and dermatology literature vary widely. We examine both classic and newly developed therapeutic agents and modalities for cutaneous leishmaniasis. Proper therapy depends on species identification. New World leishmaniasis, in general, requires more aggressive therapy; parenteral antimonials are the drugs of choice. Physical modalities may suffice in most cases of Old World leishmaniasis because of its strong tendency toward spontaneous resolution.

引用

页码：693 / 708

页数：16

共 112 条

[1] ADMINISTRATION OF RECOMBINANT INTERLEUKIN-2 REDUCES THE LOCAL PARASITE LOAD OF PATIENTS WITH DISSEMINATED CUTANEOUS LEISHMANIASIS [J].